Abstract
Brain hemorrhage is a serious complication of tissue plasminogen activator (tPA) therapy for ischemic stroke. Here we report that activated protein C (APC), a plasma serine protease with systemic anticoagulant, anti-inflammatory and antiapoptotic activities, and direct vasculoprotective and neuroprotective activities, blocks tPA-mediated brain hemorrhage after transient brain ischemia and embolic stroke in rodents. We show that APC inhibits a pro-hemorrhagic tPA-induced, NF-κB–dependent matrix metalloproteinase-9 pathway in ischemic brain endothelium in vivo and in vitro by acting through protease-activated receptor 1. The present findings suggest that APC may improve thrombolytic therapy for stroke, in part, by reducing tPA-mediated hemorrhage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
20 March 2024
An Editorial Expression of Concern to this paper has been published: https://doi.org/10.1038/s41591-024-02911-0
References
NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28, 2109–2118 (1997).
Wang, X. et al. Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313–1317 (2003).
Asahi, M. et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724–7732 (2001).
Lapchak, P.A., Chapman, D.F., Zivin, J.A. & Hsu, C.Y. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)–induced hemorrhage after thromboembolic stroke. Stroke 31, 3034–3040 (2000).
Sumii, T. & Lo, E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33, 831–836 (2002).
Pfefferkorn, T. & Rosenberg, G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34, 2025–2030 (2003).
Montaner, J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107, 598–603 (2003).
Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186–1190 (2002).
Gu, Z. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401–6408 (2005).
Zlokovic, B.V. Remodeling after stroke. Nat. Med. 12, 390–391 (2006).
Joyce, D.E. et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276, 11199–11203 (2001).
Riewald, M. et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882 (2002).
Cheng, T. et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9, 338–342 (2003).
Guo, H. et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41, 563–572 (2004).
Finigan, J.H. et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem. 280, 17286–17293 (2005).
Feistritzer, C. & Riewald, M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1–phosphate receptor-1 crossactivation. Blood 105, 3178–3184 (2005).
Bernard, G. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).
Liu, D. et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat. Med. 10, 1379–1383 (2004).
Zlokovic, B.V. et al. Functional recovery after embolic stroke in rodents by activated protein C. Ann. Neurol. 58, 474–477 (2005).
Zhang, L. et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112, 3486–3499 (2005).
Zhang, Z. et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106, 740–745 (2002).
Deane, R. et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43, 333–344 (2004).
Herrmann, O. et al. IKK mediates ischemia-induced neuronal death. Nat. Med. 11, 1322–1329 (2005).
Laderoute, K.R. The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. Semin. Cell. Develop. Biol. 16, 502–513 (2005).
Sanchez, J.F. et al. Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor B signaling. Mol. Cell. Biol. 23, 4649–4662 (2003).
Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827–839 (2003).
Riewald, M. & Ruf, M. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. 280, 19808–19814 (2005).
Nurmi, A. et al. Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J. Neurochem. 91, 755–765 (2004).
Junge, C.E. et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 100, 13019–13024 (2003).
Zhao, B.Q. et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12, 441–445 (2006).
Wu, Z., Hofman, F.M. & Zlokovic, B.V. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J. Neurosci. Methods 130, 53–63 (2003).
Bernard, G.R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Eng. J. Med. 344, 699–709 (2001).
Fernandez, J. et al. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol. Dis. 30, 271–276 (2003).
Ludemann, M.J. et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J. Biol. Chem. 280, 13122–13128 (2005).
Mosnier, L.O. & Griffin, J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial protein C receptor. Biochem. J. 373, 65–70 (2003).
Domotor, E. et al. Activated protein C alters cytosolic Ca2+ flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 101, 4797–4801 (2003).
Zivin, J.A. et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230, 1289–1292 (1985).
Nicole, O. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59–64 (2001).
Wang, Y.F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228–231 (1998).
Matys, T. & Strickland, S. Tissue plasminogen activator and NMDA receptor cleavage. Nat. Med. 9, 371–373 (2003).
Zhang, R.L. et al. A rat model of focal embolic cerebral ischemia. Brain Res. 766, 83–92 (1997).
Li, Y., Lu, W. & Bu, G. Essential role of low density liproprotein receptor-related protein in vascular smooth muscle cell migration. FEBS Lett. 555, 346–350 (2003).
Ye, X. et al. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem. Biophys. Res. Commun. 259, 671–677 (1999).
Acknowledgements
We thank A. Sagare for radiolabeling tPA. Par1-null mice were provided by S. Coughlin (University of California San Francisco), EPCR by K. Fukudome (Department of Immunology, Saga Medical School), and the adenoviruses for BEC transduction by S. Maggirwar (University of Rochester). This work was supported by US National Institutes of Health grant HL63290 to B.V.Z.
Author information
Authors and Affiliations
Contributions
T.C. conducted and performed in vitro studies of human BEC. A.L.P. conducted and performed in vivo stroke studies in the mouse MCA model. Z.L. conducted and performed in vivo stroke studies in the rat embolic model. M.T. performed in vivo studies in Par1-null mice. Z.Z. performed in vitro studies in mouse BEC. Z.W. performed immunostaining studies. D.L. performed in vivo mouse MCA studies. S.B.M. performed in vitro studies and developed IkkB reagent for the study. R.D. conducted and performed studies of physiological parameters. J.A.F. prepared different preparations of mouse and human APC. B.L. performed physiological analysis in mouse models and in vitro assays. J.H.G. contributed to experimental design and data discussion and analysis. M.C. designed studies in rat embolic model, and contributed to data analysis and interpretation. B.V.Z. designed the entire study, supervised all segments of the study, and wrote the manuscript.
Note: Supplementary information is available on the Nature Medicine website.
Corresponding author
Ethics declarations
Competing interests
B.V.Z. is scientific founder of Socratech LLC, a start-up biotech company with a mission to develop neuroprotective strategies in the aging and diseased brain such as Alzheimer's and stroke.
Supplementary information
Supplementary Fig. 1
Immunostaining of collagen IV after transient ischemia in mice determined at 24 h. (PDF 401 kb)
Supplementary Fig. 2
Immunostaining of ZO1 and CD-31 after transient ischemia in mice determined at 24 h. (PDF 1189 kb)
Supplementary Fig. 3
Gelatinolytic activity of recombinant pro-MMP9 and active-MMP-9 on SDS-PAGE. (PDF 258 kb)
Supplementary Fig. 4
SDS-PAGE analysis of 125I-labeled tPA in the absence and presence of APC (400 nM). (PDF 224 kb)
Supplementary Fig. 5
Plasma levels of mouse APC (ng/ml) determined by mouse specific APC ELISA after intravenous administration of mouse APC. (PDF 275 kb)
Supplementary Table 1
Physiological parameters before MCAO, during MCAO and 60 min after MCAO. (PDF 65 kb)
Rights and permissions
About this article
Cite this article
Cheng, T., Petraglia, A., Li, Z. et al. Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage. Nat Med 12, 1278–1285 (2006). https://doi.org/10.1038/nm1498
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1498